Hosted on MSN

Praxis Precision Medicines’ PRAX-628 Study: A Potential Game-Changer for Focal Seizures

Praxis Precision Medicines, Inc. ((PRAX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Seeking Alpha

Praxis: Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts

The last time I spoke about Praxis Precision Medicines, Inc. (PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At that ...
Nasdaq

Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
MarketWatch

Praxis Converts Elsunersen Study to Single-Arm Design After FDA Meeting

Praxis Precision Medicines is converting its EMBRAVE3 study of elsunersen for children suffering from a developmental disease into a single-arm study after meeting with the Food and Drug ...